Posted by Michael Wonder on 23 Jun 2022
FDA explains when it will rescind breakthrough designations
23 June 2022 - The US FDA on Thursday released draft guidance explaining its thought process for rescinding breakthrough therapy designation during its evaluation of a drug.
While FDA has long asserted its authority to rescind or withdraw breakthrough therapy designations, the new guidance will add clarity for sponsors as to when the agency might revoke the designation.
